A daily 40 mg dose of the undenatured type II collagen was superior to 1500 mg glucosamine hydrochloride + 1200 mg chondroitin sulfate or a placebo for 180 days, according to data presented by Zainulabedin Saiyed, PhD, InterHealth’s director of R&D.
Pooled results from two identically designed, randomized, double-blind, placebo-controlled studies in people with osteoarthritis indicated that statistically significant reductions in overall WOMAC score was observed in the UC-II group compared to placebo (p=0.0026) and the glucosamine-chondroitin group (p=0.047).
Driving the change in overall WOMAC score for the UC-II group were statistically significant reductions in the WOMAC pain, stiffness and physical function subscales, said Dr Saiyed.
In addition, the UC-II also exhibited significant reductions in total Lequesne Functional Index (LFI) and mean Visual Analog Scale (VAS), compared to placebo and the glucosamine-chondroitin group.
A spokesperson for InterHealth told us that the company has plans to publish in top-rated peer-reviewed journal. “We are currently preparing the manuscript,” they said.
UC-II, a patented form of undenatured type II collagen derived from chicken sternum, holds novel foods status in Europe.
Source: 2015 Scripps Natural Supplement Conference: Natural Supplements: An Evidence-Based Update
Friday, January 16 - Sunday, January 18, 2015, San Diego, California
“Efficacy and tolerability of undenatured type ii collagen supplement in modulating knee joint function”
Authors: Z.M. Saiyed, J.F. Hull, J.P Lugo